Literature DB >> 8452324

Acute mountain sickness in a general tourist population at moderate altitudes.

B Honigman1, M K Theis, J Koziol-McLain, R Roach, R Yip, C Houston, L G Moore, P Pearce.   

Abstract

OBJECTIVE: To determine the incidence of acute mountain sickness in a general population of visitors to moderate elevations, the characteristics associated with it, and its effect on physical activity.
DESIGN: A cross-sectional study.
SETTING: Resort communities located at 6300 to 9700 feet elevation in the Rocky Mountains of Colorado. PARTICIPANTS: Convenience sample of 3158 adult travelers, 16 to 87 years old (mean age [+/- SD], 43.8 +/- 11.8 years).
RESULTS: Twenty-five percent of the travelers to moderate elevations developed acute mountain sickness, which occurred in 65% of travelers within the first 12 hours of arrival. Fifty-six percent of those with symptoms reduced their physical activity. The odds favoring acute mountain sickness were 3.5 times as large for visitors whose permanent residence was below 3000 feet elevation as for those whose residence was above 3000 feet; 2.8 times as large for visitors with previous symptoms of acute mountain sickness; and twice as large in travelers younger than 60 years. Women, obese persons, those in poor or average physical condition, and those with underlying lung disease also had a higher occurrence of acute mountain sickness (P < 0.05).
CONCLUSIONS: Acute mountain sickness occurs in 25% of visitors to moderate altitudes and affects activity in most symptomatic visitors. Persons who are younger, less physically fit, live at sea level, have a history of acute mountain sickness, or have underlying lung problems more often develop these symptoms.

Entities:  

Mesh:

Year:  1993        PMID: 8452324     DOI: 10.7326/0003-4819-118-8-199304150-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  70 in total

1.  Acute mountain sickness: the "poison of the pass"

Authors: 
Journal:  West J Med       Date:  2000-06

2.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

3.  Intraocular pressure changes during high-altitude acclimatization.

Authors:  Mitrofanis Pavlidis; Tobias Stupp; Ilias Georgalas; Evi Georgiadou; Michail Moschos; Solon Thanos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-13       Impact factor: 3.117

4.  Prediction of the susceptibility to AMS in simulated altitude.

Authors:  Martin Burtscher; Christoph Szubski; Martin Faulhaber
Journal:  Sleep Breath       Date:  2008-05       Impact factor: 2.816

5.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

Review 6.  Special Considerations in Medical Screening for Participants in Remote Endurance Events.

Authors:  Jeremy Joslin; Martin D Hoffman; Ian Rogers; Robert M Worthing; Matt Ladbrook; Joshua Mularella
Journal:  Sports Med       Date:  2015-08       Impact factor: 11.136

Review 7.  High altitude pilgrimage medicine.

Authors:  Buddha Basnyat
Journal:  High Alt Med Biol       Date:  2014-12       Impact factor: 1.981

8.  Performance at altitude and angiotensin I-converting enzyme genotype.

Authors:  G Tsianos; K I Eleftheriou; E Hawe; L Woolrich; M Watt; I Watt; A Peacock; H Montgomery; S Grant
Journal:  Eur J Appl Physiol       Date:  2004-12-01       Impact factor: 3.078

Review 9.  Working in permanent hypoxia for fire protection-impact on health.

Authors:  Peter Angerer; Dennis Nowak
Journal:  Int Arch Occup Environ Health       Date:  2003-01-31       Impact factor: 3.015

10.  Non-invasive positive pressure ventilation during sleep at 3800 m: Relationship to acute mountain sickness and sleeping oxyhaemoglobin saturation.

Authors:  Pamela L Johnson; Daniel A Popa; G Kim Prisk; Natalie Edwards; Colin E Sullivan
Journal:  Respirology       Date:  2009-12-27       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.